Table I.
Age and ECOG PS of adults with breast cancer included in registration studies of targeted therapies
| Class | Agent | Trial | Age | ECOG PS | ||||
|---|---|---|---|---|---|---|---|---|
| Total | ≥ 65 years | ≥ 70 years | 0 | 1 | 2 | |||
| CDK 4/6 Inhibitor | Abemaciclib | MONARCH-1 [53] | 132 | 42 (31.8%) | NR | 73 (55.3%) | 59 (44.7%) | NR |
| MONARCH-2 [48] | 493 | 222 (45%) | NR | 296 (60%) | 197 (39.9%) | NR | ||
| MONARCH-3 [44] | 493 | 222 (45%) | NR | 296 (60%) | 197 (39.9%) | NR | ||
| Palbociclib | PALOMA-1 [96] | 165 | 76 (46%) | NR | 91 (55.2%) | 74 (44.8%) | NR | |
| PALOMA-2 [41] | 666 | 262 (39.3%) | NR | 359 (53.9%) | 295 (44.3%) | 12 (1.8%) | ||
| PALOMA-3 [46] | 521 | NR | NR | 322 (61.8%) | 199 (38.2%) | NR | ||
| Ribociclib | MONALEESA-2 [39] | 668 | 295 (44.2%) | NR | 407 (60.9%) | 261 (39.1%) | NR | |
| MONALEESA-3 [47] | 726 | 339 (46.7%) | NR | 468 (64.5%) | 256 (35.3%) | NR | ||
| PI3K Inhibitor | Alpelisib | SOLAR-1 [62] | 572 | NR | NR | 388 (67.8%) | 181 (31.6%) | NR |
| mTOR Inhibitor | Everolimus | BOLERO-2 [71] | 724 | 275 (37.9%) | 164 (22.7%) | 435 (60.1%) | 258 (35.6%) | 16 (2.21%) |
NR = Not Reported